Wall Street brokerages expect Oxford Immunotec Global PLC (NASDAQ:OXFD) to post earnings of ($0.20) per share for the current fiscal quarter, Zacks reports. Three analysts have issued estimates for Oxford Immunotec Global’s earnings. The highest EPS estimate is ($0.15) and the lowest is ($0.27). Oxford Immunotec Global reported earnings per share of ($0.40) during the same quarter last year, which would indicate a positive year over year growth rate of 50%. The firm is scheduled to report its next earnings report on Tuesday, May 7th.

On average, analysts expect that Oxford Immunotec Global will report full-year earnings of ($0.47) per share for the current fiscal year, with EPS estimates ranging from ($0.76) to ($0.29). For the next financial year, analysts forecast that the business will report earnings of ($0.29) per share, with EPS estimates ranging from ($0.52) to ($0.16). Zacks’ EPS calculations are an average based on a survey of analysts that cover Oxford Immunotec Global.

Oxford Immunotec Global (NASDAQ:OXFD) last posted its earnings results on Monday, March 11th. The company reported $1.25 EPS for the quarter, topping analysts’ consensus estimates of ($0.19) by $1.44. The company had revenue of $15.37 million for the quarter, compared to the consensus estimate of $18.61 million. Oxford Immunotec Global had a return on equity of 14.26% and a net margin of 147.71%.

A number of equities research analysts recently commented on the company. Zacks Investment Research upgraded Oxford Immunotec Global from a “hold” rating to a “buy” rating and set a $19.00 target price on the stock in a research report on Wednesday. ValuEngine downgraded Oxford Immunotec Global from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, March 12th. Piper Jaffray Companies assumed coverage on Oxford Immunotec Global in a research report on Friday, March 8th. They issued an “overweight” rating on the stock. Finally, BidaskClub upgraded Oxford Immunotec Global from a “sell” rating to a “hold” rating in a research report on Thursday, February 7th. One equities research analyst has rated the stock with a hold rating and four have given a buy rating to the company. The company presently has a consensus rating of “Buy” and a consensus price target of $19.00.

In other Oxford Immunotec Global news, CEO Peter Wrighton-Smith sold 10,000 shares of the business’s stock in a transaction that occurred on Tuesday, February 19th. The stock was sold at an average price of $16.99, for a total transaction of $169,900.00. Following the sale, the chief executive officer now directly owns 413,469 shares of the company’s stock, valued at $7,024,838.31. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, SVP Elizabeth M. Keiley sold 4,100 shares of the business’s stock in a transaction that occurred on Monday, March 4th. The stock was sold at an average price of $17.00, for a total value of $69,700.00. Following the sale, the senior vice president now directly owns 26,928 shares in the company, valued at $457,776. The disclosure for this sale can be found here. Insiders sold 27,100 shares of company stock worth $431,450 over the last quarter. 6.61% of the stock is owned by company insiders.

Hedge funds and other institutional investors have recently modified their holdings of the business. Renaissance Technologies LLC increased its stake in Oxford Immunotec Global by 390.5% during the third quarter. Renaissance Technologies LLC now owns 103,300 shares of the company’s stock worth $1,677,000 after acquiring an additional 82,242 shares during the last quarter. Wells Fargo & Company MN increased its stake in Oxford Immunotec Global by 11.2% during the third quarter. Wells Fargo & Company MN now owns 45,820 shares of the company’s stock worth $744,000 after acquiring an additional 4,605 shares during the last quarter. Stonepine Capital Management LLC bought a new stake in Oxford Immunotec Global during the third quarter worth approximately $3,666,000. First Light Asset Management LLC increased its stake in Oxford Immunotec Global by 28.5% during the third quarter. First Light Asset Management LLC now owns 1,594,009 shares of the company’s stock worth $25,871,000 after acquiring an additional 353,618 shares during the last quarter. Finally, Essex Investment Management Co. LLC increased its stake in Oxford Immunotec Global by 2.0% during the fourth quarter. Essex Investment Management Co. LLC now owns 174,499 shares of the company’s stock worth $2,230,000 after acquiring an additional 3,482 shares during the last quarter. 89.92% of the stock is currently owned by institutional investors.

Shares of NASDAQ:OXFD traded down $0.13 during mid-day trading on Tuesday, reaching $18.20. The stock had a trading volume of 255,706 shares, compared to its average volume of 141,663. The company has a market capitalization of $479.77 million, a P/E ratio of 35.69 and a beta of 0.36. Oxford Immunotec Global has a 1 year low of $11.66 and a 1 year high of $19.19.

Oxford Immunotec Global Company Profile

Oxford Immunotec Global PLC, a diagnostics company, focuses on developing and commercializing proprietary tests for underserved immune-regulated conditions. Its development activities principally focus on the areas of infectious diseases, transplantation, autoimmune and inflammatory disease, and immune-oncology.

Recommended Story: Why investors pay attention to retained earnings

Get a free copy of the Zacks research report on Oxford Immunotec Global (OXFD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Earnings History and Estimates for Oxford Immunotec Global (NASDAQ:OXFD)

Receive News & Ratings for Oxford Immunotec Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Oxford Immunotec Global and related companies with MarketBeat.com's FREE daily email newsletter.